The Cohort Study of Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection

Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection Clinical Trial

Official title:

The Cohort Study of Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03377972
• Other study ID #: B2017-130
• Status: Not yet recruiting
• Phase: N/A
• First received: November 12, 2017
• Last updated: December 16, 2017
• Start date: January 1, 2018
• Est. completion date: December 1, 2018

Study information

• Verified date: December 2017
• Source: Shanghai Zhongshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Endoscopic Submucosal Dissection (ESD) is currently the main method of treatment of early esophageal cancer and precancerous lesions. Therefore, the investigators are looking forward to conduct a cohort study on early esophageal cancer patients undergoing endoscopic treatment collected from Zhongshan Hospital, Fudan University, comparing the WHO standard with Japanese standard of endoscopic therapy diagnosis. In addition，the investigators will collect patients' detailed informations and analyze the risk factors for metastasis and recurrence of early esophageal cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: December 1, 2018
• Est. primary completion date: December 1, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

1. Older than 15-year-old

2. Undergoing endoscopic Submucosal Dissection (ESD) in ZhongShan Hospital

Exclusion Criteria:

Preoperative patients with recurrence and Lost to follow-up of patients within 1 year

Related Conditions & MeSH terms

• Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection
• Esophageal Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison WHO diagnosis standard with JAPAN in Early Esophageal Cancer patients by accessing pathological section.	Comparison WHO diagnosis standard with JAPAN in Early Esophageal Cancer patients by accessing pathological section.	December 1st,2017-December 1st,2018